Welcome to our dedicated page for Swk Hldgs news (Ticker: SWKH), a resource for investors and traders seeking the latest updates and insights on Swk Hldgs stock.
SWK Holdings Corp (NASDAQ: SWKH) - a leader in specialized healthcare finance - provides investors and industry stakeholders with critical updates through this centralized news hub. Track all official announcements, strategic developments, and financial disclosures from the company pioneering non-dilutive funding solutions for life science innovators.
This resource delivers verified SWKH news including earnings reports, royalty financing agreements, partnership announcements, and regulatory filings. Investors gain timely access to:
- Quarterly financial performance updates
- Strategic acquisitions and asset purchases
- Enteris BioPharma development milestones
- Portfolio company progress reports
Bookmark this page for direct access to SWK Holdings' latest press releases and market-moving developments. Our curated news collection eliminates fragmented research, providing a reliable single source for monitoring the company's healthcare finance activities and pharmaceutical sector impact.
SWK Holdings Corporation (SWKH) announced significant corporate changes and financial results for Q4 2022. Jody Staggs has been named CEO, and Laurie Dotter will chair the board. The company expects quarterly operating expenses to decrease by over $1 million by Q3 2023. Q4 revenue fell 34.5% to $9.8 million, primarily due to a reduction in Pharmaceutical Development revenue. GAAP net income was $2.8 million, down from $6.3 million YoY, reflecting a pre-tax loss of $4.4 million. Investment assets increased by 25.4% to $237.9 million. The company remains focused on sustainable growth within the life sciences sector.
SWK Holdings Corporation (Nasdaq: SWKH), a specialty finance firm focused on life sciences, is set to host a conference call and live audio webcast on April 3, 2023, at 10:00 a.m. ET. The call will cover the corporate and financial results for the fourth quarter and full year of 2022. Interested investors can participate by calling (844) 378-6488 (U.S.) or (412) 317-1079 (International), or by accessing the webcast on the company's website. SWK specializes in non-dilutive financing for small- and mid-sized healthcare companies, providing flexible funding solutions ranging from $5.0 million to $25.0 million.
FAQ
What is the current stock price of Swk Hldgs (SWKH)?
What is the market cap of Swk Hldgs (SWKH)?
